MTOR and Huntington disease: Rubinsztein’s group demonstrated that activation of autophagy following mTOR inhibition by rapamycin could reduce aggregate-prone proteins and increase the removal of the aggregates in protein conformational disorders (PCD), such as Huntington’s disease (HD), suggesting the clinical application of rapamycin in HD [414].